Ackerman Cancer Center, a leading institution in personalized oncology care, is proud to announce its adoption of MyoStrain, a cutting-edge cardiac assessment technology.
MORRISVILLE, N.C., Jan. 6, 2025 /PRNewswire-PRWeb/ -- Ackerman Cancer Center, a leading institution in personalized oncology care, is proud to announce its adoption of MyoStrain, a cutting-edge cardiac assessment technology. This partnership underscores Ackerman Cancer Center's commitment to providing state-of-the-art care and prioritizing the overall health and wellness of its patients.
Myostrain, developed by Myocardial Solutions, is enhanced cardiac software that provides novel clinical information to help physicians risk stratify, detect and manage cardiac dysfunction from patients at risk of heart failure and oncological patients at risk of cardio toxicity from cancer treatments in 10 minutes. MyoStrain is particularly valuable for cancer patients, as it provides early detection and helps physicians prevent cardiac dysfunction related to cancer treatments such as chemotherapy and radiation. By leveraging MyoStrain, Ackerman Cancer Center aims to proactively monitor and protect heart health throughout a patient's treatment journey.
Enhanced Care for Cancer Patients
The integration of MyoStrain into Ackerman Cancer Center's clinical protocols ensures that patients receive comprehensive care. Cancer therapies, while lifesaving, can pose risks to cardiovascular health. MyoStrain's ability to detect subtle changes in cardiac performance allows clinicians to tailor treatment plans, minimize risks, and improve long-term outcomes for patients.
Dr. Ackerman stated, "We are excited to be the first center in Florida to offer Cardiac MRI scans with MyoStrain. This will allow us to closely monitor the patient's heart during their cancer treatment."
About MyoStrain
Myocardial Solutions (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI's proprietary technology, MyoStrain®, is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction.
About Ackerman Cancer Center
Ackerman Cancer Center is renowned for its patient-centered approach to oncology care. With a focus on innovative treatments, compassionate support, and cutting-edge technology, the center provides personalized care to patients across a wide range of cancer types. The adoption of MyoStrain reflects its dedication to integrating the latest medical advancements to benefit patients.
Looking Ahead
Ackerman Cancer Center's use of MyoStrain marks an exciting milestone in its mission to deliver comprehensive cancer care. The center invites patients and the broader community to learn more about how this technology is shaping the future of oncology and cardiac health.
For more information, please visit www.myocardialsolutions.com.
Media Contact: Linda Horne
919-459-9104
linda.horne@myocardailsolutions.com
Media Contact
Linda Horne, Myocardial Solutions, 1 919-459-9104, linda.horne@myocardialsolutions.com, https://www.myocardialsolutions.com/
SOURCE Myocardial Solutions
Share this article